id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S9442 R33159 |
Ban (Valproate) (Mixed indications) (Controls exposed to Lamotrigine, sick), 2015 | Genital system anomaly | 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
2.57 [0.23;28.49] C excluded (control group) |
2/214 1/273 | 3 | 214 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9443 R33164 |
Ban (Valproate) (Mixed indications) (Controls unexposed NOS), 2015 | Genital system anomaly | 1st trimester | prospective cohort | unexposed (general population or NOS) | Adjustment: No | 2.36 [0.59;9.52] C | 2/214 1,023/257,153 | 1,025 | 214 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9325 R32510 |
Veiby (Valproate) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2014 | Genital | throughout pregnancy | population based cohort retrospective | exposed to other treatment, sick | Adjustment: No | 3.80 [1.07;13.56] C | 6/333 4/833 | 10 | 333 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9330 R32543 |
Artama (Valproate), 2005 | Genital organs | 1st trimester | retrospective cohort (registry) | unexposed, sick | Adjustment: No | 3.62 [1.04;12.60] C | 5/263 5/939 | 10 | 263 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 3 studies | 3.25 [1.54;6.89] | 1,045 | 810 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Valproate) (Mixed indications) (Controls unexposed NOS; 2: Valproate) (Controls exposed to Lamotrigine, sick) (Mixed indications; 3: Valproate;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 9442